| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Deepak Cyril D'Souza, Brian Pittman, Edward Perry, Arthur Sime. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology. vol 202. issue 4. 2009-08-11. PMID:18807247. |
acute and chronic exposure to cannabinoids has been associated with cognitive deficits, a higher risk for schizophrenia and other drug abuse. |
2009-08-11 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Mohini Ranganathan, Deepak Cyril D'Souz. Cannabinoids and psychosis. International review of psychiatry (Abingdon, England). vol 21. issue 2. 2009-08-04. PMID:19367509. |
pharmacological studies show that cannabinoids can induce a full range of transient positive, negative, and cognitive symptoms in healthy individuals that are similar to those seen in schizophrenia. |
2009-08-04 |
2023-08-12 |
Not clear |
| Dagmar Koethe, Andrea Giuffrida, Daniela Schreiber, Martin Hellmich, Frauke Schultze-Lutter, Stefan Ruhrmann, Joachim Klosterkötter, Daniele Piomelli, F Markus Lewek. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. The British journal of psychiatry : the journal of mental science. vol 194. issue 4. 2009-08-03. PMID:19336792. |
this anandamidergic up-regulation in the initial prodromal course may suggest a protective role of the endocannabinoid system in early schizophrenia. |
2009-08-03 |
2023-08-12 |
human |
| Glenn Schwarcz, Basawaraj Karajgi, Richard McCarth. Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. Journal of clinical psychopharmacology. vol 29. issue 3. 2009-08-03. PMID:19440079. |
we are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic delta-9-tetrahydrocannabinol). |
2009-08-03 |
2023-08-12 |
Not clear |
| Glenn Schwarcz, Basawaraj Karajgi, Richard McCarth. Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. Journal of clinical psychopharmacology. vol 29. issue 3. 2009-08-03. PMID:19440079. |
they open a possible new role for cannabinoids in the treatment of schizophrenia. |
2009-08-03 |
2023-08-12 |
Not clear |
| Danai Dima, Jonathan P Roiser, Detlef E Dietrich, Catharina Bonnemann, Heinrich Lanfermann, Hinderk M Emrich, Wolfgang Dill. Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling. NeuroImage. vol 46. issue 4. 2009-07-29. PMID:19327402. |
towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to a dysregulation of the endogenous cannabinoid system. |
2009-07-29 |
2023-08-12 |
human |
| Dilshani W N Dissanayake, Margarita Zachariou, Charles A Marsden, Robert Maso. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2. Neuropharmacology. vol 55. issue 8. 2009-04-15. PMID:18809420. |
dysregulation of the endocannabinoid system has been proposed to be involved in the pathogenesis of schizophrenia. |
2009-04-15 |
2023-08-12 |
rat |
| Jenny L Wiley, Seth H Kendler, James J Burston, Daniel R Howard, Dana E Selley, Laura J Sim-Selle. Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology. vol 55. issue 7. 2009-01-26. PMID:18708079. |
dysregulation of the endocannabinoid and dopamine systems has been implicated in schizophrenia. |
2009-01-26 |
2023-08-12 |
rat |
| M López-Gallardo, R Llorente, A Llorente-Berzal, E M Marco, C Prada, V Di Marzo, M P Vivero. Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Developmental neurobiology. vol 68. issue 12. 2008-11-26. PMID:18726913. |
the present results provide new insights regarding the psychopathological implications of the cerebellum, the role of the endocannabinoid system in neural development, and the possible neurodevelopmental basis of gender differences in schizophrenia. |
2008-11-26 |
2023-08-12 |
rat |
| Patrik Roser, Georg Juckel, Johannes Rentzsch, Thomas Nadulski, Jürgen Gallinat, Andreas M Stadelman. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 18. issue 8. 2008-11-05. PMID:18544469. |
given the psychotic-like effects of delta9-thc, a cannabinoid hypothesis of schizophrenia has been proposed. |
2008-11-05 |
2023-08-12 |
human |
| Stéphane Potvin, Edouard Kouassi, Olivier Lipp, Roch-Hugo Bouchard, Marc-André Roy, Marie-France Demers, Alain Gendron, Giuseppe Astarita, Daniele Piomelli, Emmanuel Sti. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of psychopharmacology (Oxford, England). vol 22. issue 3. 2008-10-23. PMID:18308802. |
endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. |
2008-10-23 |
2023-08-12 |
human |
| Stéphane Potvin, Edouard Kouassi, Olivier Lipp, Roch-Hugo Bouchard, Marc-André Roy, Marie-France Demers, Alain Gendron, Giuseppe Astarita, Daniele Piomelli, Emmanuel Sti. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of psychopharmacology (Oxford, England). vol 22. issue 3. 2008-10-23. PMID:18308802. |
disturbances in the endogenous cannabinoid (ecb) system in schizophrenia may contribute to their enhanced sensitivity to psychoactive substances, and the beneficial effects of second-generation antipsychotics for substance abuse in schizophrenia may involve modulatory effects on ecb. |
2008-10-23 |
2023-08-12 |
human |
| Kirsten R Müller-Vahl, Hinderk M Emric. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert review of neurotherapeutics. vol 8. issue 7. 2008-10-01. PMID:18590475. |
cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. |
2008-10-01 |
2023-08-12 |
Not clear |
| Kirsten R Müller-Vahl, Hinderk M Emric. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert review of neurotherapeutics. vol 8. issue 7. 2008-10-01. PMID:18590475. |
there are several lines of evidence suggesting that, at least in a subgroup of patients, alterations in the endocannabinoid system may contribute to the pathogenesis of schizophrenia (e.g., increased density of cb(1) receptor binding and increased levels of cerebrospinal fluid endocannabinoid anandamide). |
2008-10-01 |
2023-08-12 |
Not clear |
| Stephen M Eggan, Takanori Hashimoto, David A Lewi. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Archives of general psychiatry. vol 65. issue 7. 2008-09-04. PMID:18606950. |
reduced cortical cannabinoid 1 receptor messenger rna and protein expression in schizophrenia. |
2008-09-04 |
2023-08-12 |
Not clear |
| Martin Cohen, Nadia Solowij, Vaughan Car. Cannabis, cannabinoids and schizophrenia: integration of the evidence. The Australian and New Zealand journal of psychiatry. vol 42. issue 5. 2008-08-14. PMID:18473254. |
cannabis, cannabinoids and schizophrenia: integration of the evidence. |
2008-08-14 |
2023-08-12 |
Not clear |
| Martin Cohen, Nadia Solowij, Vaughan Car. Cannabis, cannabinoids and schizophrenia: integration of the evidence. The Australian and New Zealand journal of psychiatry. vol 42. issue 5. 2008-08-14. PMID:18473254. |
the aim is to assist clinicians to probe more deeply into the newly unfolding world of cannabinoid physiology and to critically evaluate the potential role of cannabis in the onset and persistence of cognitive impairments and psychosis in otherwise healthy users and in schizophrenia. |
2008-08-14 |
2023-08-12 |
Not clear |
| D T Malone, C S Kearn, L Chongue, K Mackie, D A Taylo. Effect of social isolation on CB1 and D2 receptor and fatty acid amide hydrolase expression in rats. Neuroscience. vol 152. issue 1. 2008-08-05. PMID:18082330. |
also, a dysregulation in both the endocannabinoid and dopaminergic systems has been implicated in schizophrenia. |
2008-08-05 |
2023-08-12 |
rat |
| F Markus Leweke, Dagmar Koeth. Cannabis and psychiatric disorders: it is not only addiction. Addiction biology. vol 13. issue 2. 2008-07-08. PMID:18482435. |
since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the role of this system in major psychiatric disorders like schizophrenia (scz), bipolar disorder (bd), major depression and anxiety disorder. |
2008-07-08 |
2023-08-12 |
Not clear |
| Susana Vaz Carneiro, Mário Borreg. [Psychosis and substance abuse]. Acta medica portuguesa. vol 20. issue 5. 2008-04-08. PMID:18282438. |
in the light of current scientific knowledge, this is very relevant fact since the use of cannabinoids appears to be a risk factor for the onset of schizophrenia. |
2008-04-08 |
2023-08-12 |
Not clear |